Get started
Author

Annette Reichardt

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
2015 · Heikki Joensuu, Mikael Eriksson, et al. · Journal of Clinical Oncology · 234
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
2020 · Heikki Joensuu, Mikael Eriksson, et al. · JAMA Oncology · 199
PDF
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib
2017 · Heikki Joensuu, Eva Wardelmann, et al. · JAMA Oncology · 189
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
2009 · George D. Demetri, Paolo G. Casali, et al. · Clinical Cancer Research · 111
PDF
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
2011 · H. Joensuu, M. Eriksson, et al. · Journal of Clinical Oncology · 79
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence?
2016 · Mikael Eriksson, Peter Reichardt, et al. · European Journal of Cancer · 50
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
2014 · S Bauer, R A Hilger, et al. · British Journal of Cancer · 50
PDF
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
2011 · H. Joensuu, M. Eriksson, et al. · Journal of Clinical Oncology · 49
Decreased Incidence of Oncology Admissions in 75 Helios Hospitals in Germany during the COVID-19 Pandemic
2020 · Peter Reichardt, Andreas Bollmann, et al. · Oncology Research and Treatment · 35
PDF
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2023 · Heikki Joensuu, Eva Wardelmann, et al. · Clinical Cancer Research · 30
PDF
Molecular Targeted Therapy of Gastrointestinal Stromal Tumors
2011 · P. Reichardt, A. Reichardt, et al. · Current Cancer Drug Targets · 22
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
2024 · Heikki Joensuu, Annette Reichardt, et al. · British Journal of Cancer · 20
Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
2023 · Anna Stoliaroff-Pepin, Caroline Peine, et al. · Infection · 14
PDF
Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022
2022 · Anna Stoliaroff-Pepin, Caroline Peine, et al. · Vaccine · 13
PDF
Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial.
2015 · Heikki Joensuu, Mikael Eriksson, et al. · Journal of Clinical Oncology · 11
Gastrointestinaler Stromatumor (GIST): Aktueller Stand der multimodalen Therapie
2011 · P. Reichardt, A. Reichardt · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · 7
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.
2020 · Heikki Joensuu, Mikael Eriksson, et al. · Journal of Clinical Oncology · 6
Early Myocardial Oedema can Predict Subsequent Cardiomyopathy in High-Dose Anthracycline Therapy
2022 · Fabian Muehlberg, Markus Kornfeld, et al. · ESC Heart Failure · 5
PDF
Gastrointestinale Stromatumoren (GIST)
2013 · P. Reichardt, A. Reichardt · DMW - Deutsche Medizinische Wochenschrift · 5
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST).
2012 · Sebastian Bauer, Ralf A. Hilger, et al. · Journal of Clinical Oncology · 4
The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST—Second annual summary.
2010 · M. Chacon, P. Reichardt, et al. · Journal of Clinical Oncology · 2
Study Protocol from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2023 · Heikki Joensuu, Eva Wardelmann, et al. · 1
PDF
Gastrointestinale Stromatumoren
2017 · P. Reichardt, A. Reichardt, et al. · Die Gastroenterologie · 1
Supplementary Table S1 from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025 · Heikki Joensuu, Eva Wardelmann, et al.
PDF
Supplementary Figure S2 from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025 · Heikki Joensuu, Eva Wardelmann, et al.
Works count: 57
Citation count: 1,137
H-index: 13
I10-index: 15
Year
Topic
Type